CD45RA-depleted DLI

Phase 1Biologic

SSt. Jude Children's Research Hospital

CD45RA-depleted DLI is one of 2 biologic programs targeting Hematologic Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignancyNot yet recruiting

Hematologic MalignancyPhase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Hematologic Malignancy

#DrugCompanyPhaseTrials

Claritin

PPerrigo Company

Preclinical

1 2

CD45RA-depleted DLI

SSt. Jude Children's Research Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia (ALL)

NCT03849651

Q3 2028

Phase 1Not yet recruiting

Hematologic Malignancy

NCT07672964

Q3 2030

Phase 2Recruiting

Aplastic Anemia

NCT04558736

Clinical

Trials by Indication[1]

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

Aplastic Anemia1 trial

Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04558736·21 enrolled

Acute Lymphoblastic Leukemia (ALL)1 trial

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03849651·69 enrolled

Hematologic Malignancy1 trial

CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07672964·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CD45RA-depleted DLI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD45RA-depleted DLI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD45RA-depleted DLI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSt. Jude Children's Research Hospital

CD45RA-depleted DLI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Q3 2030

Trials by Indication[1]

Relapsed or Refractory Hematologic Malignancies1 trial

Aplastic Anemia1 trial

Acute Lymphoblastic Leukemia (ALL)1 trial

Hematologic Malignancy1 trial

References

Drug Info

Quick Facts

Related News